A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Trial Profile

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs TG 1050 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Transgene
  • Most Recent Events

    • 17 Jan 2018 According to a Transgene media release, more data from this trial on multiple doses of drug is expect to present at a major international conference dedicated to liver diseases in H1 2018.
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 23 Oct 2017 According to a Transgene media release, a poster describing the first promising clinical data was presented at the at the annual meeting of the AASLD (American Association for the Study of Liver Diseases) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top